Critical Review: Entrada Therapeutics (NASDAQ:TRDA) & Propanc Biopharma (NASDAQ:PPCB)

Entrada Therapeutics (NASDAQ:TRDA) and Propanc Biopharma (NASDAQ:PPCB) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their analyst recommendations, dividends, profitability, earnings, institutional ownership, valuation and risk.

Analyst Ratings

This is a summary of recent ratings and price targets for Entrada Therapeutics and Propanc Biopharma, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Entrada Therapeutics	1	2	2	1	2.50
Propanc Biopharma	1	0	0	0	1.00

Entrada Therapeutics currently has a consensus target price of $18.25, suggesting a potential upside of 189.22%. Given Entrada Therapeutics’ stronger consensus rating and higher possible upside, equities research analysts plainly believe Entrada Therapeutics is more favorable than Propanc Biopharma.

Profitability

This table compares Entrada Therapeutics and Propanc Biopharma’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Entrada Therapeutics	-2,895.05%	-51.22%	-42.20%
Propanc Biopharma	N/A	-151.28%	-109.53%

Valuation & Earnings

This table compares Entrada Therapeutics and Propanc Biopharma”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Entrada Therapeutics	$5.74 million	42.69	-$143.75 million	($3.99)	-1.58
Propanc Biopharma	N/A	N/A	-$58.92 million	($0.97)	-1.78

Propanc Biopharma has lower revenue, but higher earnings than Entrada Therapeutics. Propanc Biopharma is trading at a lower price-to-earnings ratio than Entrada Therapeutics, indicating that it is currently the more affordable of the two stocks.

Institutional and Insider Ownership

86.4% of Entrada Therapeutics shares are owned by institutional investors. 9.5% of Entrada Therapeutics shares are owned by insiders. Comparatively, 28.5% of Propanc Biopharma shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Volatility and Risk

Entrada Therapeutics has a beta of -0.09, indicating that its share price is 109% less volatile than the S&P 500. Comparatively, Propanc Biopharma has a beta of 3.59, indicating that its share price is 259% more volatile than the S&P 500.

Summary

Entrada Therapeutics beats Propanc Biopharma on 9 of the 14 factors compared between the two stocks.

About Entrada Therapeutics

Entrada Therapeutics, Inc., a clinical-stage biotechnology company, develops endosomal escape vehicle (EEV) therapeutics for the treatment of multiple neuromuscular diseases. Its EEV platform develops a portfolio of oligonucleotide, antibody, and enzyme-based programs. Its therapeutic candidates, which include ENTR-601-44, which is in Phase I clinical trial for the treatment of Duchenne muscular dystrophy; and ENTR-701, which is in Phase 1/2 clinical trial for the treatment of myotonic dystrophy type 1. The company also offers ENTR-601-45 and ENTR-601-50, which are in preclinical trail for the treatment of Duchenne muscular dystrophy; and ENTR-501, an intracellular thymidine phosphorylase enzyme replacement therapy, which is in preclinical trail for the treatment of mitochondrial neurogastrointestinal encephalomyopathy. Entrada Therapeutics, Inc. has a strategic collaboration and license agreement with Vertex Pharmaceuticals Incorporated to research, develop, manufacture, and commercialize ENTR-701. The company was formerly known as CycloPorters, Inc. and changed its name to Entrada Therapeutics, Inc. in October 2017. Entrada Therapeutics, Inc. was incorporated in 2016 and is headquartered in Boston, Massachusetts.

About Propanc Biopharma

Propanc Biopharma, Inc., a biopharmaceutical company, develops cancer treatments for patients with pancreatic, ovarian, and colorectal cancer in Australia. It offers PRP, a formulation lead product that is in preclinical phase of development designed to enhance the anti-cancer effects of multiple enzymes. The company has a research collaboration with University of Jaén that undertakes the research activities for POP1 joint drug discovery program; and a joint research and drug discovery program with Universities of Jaén and Granada to investigate the changes in genetic and protein expression that occur in cancer cells. The company was formerly known as Propanc Health Group Corporation and changed its name to Propanc Biopharma, Inc. in April 2017. Propanc Biopharma, Inc. was incorporated in 2007 and is based in Camberwell, Australia.